3.4.24.56: insulysin
This is an abbreviated version!
For detailed information about insulysin, go to the full flat file.
Word Map on EC 3.4.24.56
-
3.4.24.56
-
alzheimer
-
neprilysin
-
abeta
-
hippocampus
-
dementia
-
mellitus
-
cerebral
-
morris
-
amyloid-beta
-
metalloprotease
-
maze
-
neuroprotective
-
amyloidogenic
-
tau
-
beta-amyloid
-
neurodegenerative
-
presenilin
-
endothelin-converting
-
senile
-
gamma-secretase
-
beta-protein
-
125i-insulin
-
abeta-degrading
-
hyperinsulinemia
-
metalloendopeptidase
-
bacitracin
-
beta-secretase
-
late-onset
-
amylin
-
microglia
-
medicine
-
adam10
-
non-amyloidogenic
-
glutathione-insulin
-
enzyme-1
-
b-chains
-
analysis
-
ad-like
-
anti-ide
-
exosite
-
beta-peptide
-
abeta1-40
- 3.4.24.56
- alzheimer
- neprilysin
- abeta
- hippocampus
- dementia
- mellitus
- cerebral
-
morris
- amyloid-beta
- metalloprotease
-
maze
-
neuroprotective
-
amyloidogenic
- tau
- beta-amyloid
- neurodegenerative
-
presenilin
-
endothelin-converting
-
senile
- gamma-secretase
- beta-protein
- 125i-insulin
-
abeta-degrading
- hyperinsulinemia
- metalloendopeptidase
- bacitracin
- beta-secretase
-
late-onset
- amylin
- microglia
- medicine
- adam10
-
non-amyloidogenic
-
glutathione-insulin
- enzyme-1
- b-chains
- analysis
-
ad-like
-
anti-ide
-
exosite
- beta-peptide
- abeta1-40
Reaction
Degradation of insulin, glucagon and other polypeptides. No action on proteins =
Synonyms
ADE, amyloid degrading enzyme, cgd6_5510, EC 3.4.22.11, EC 3.4.99.10, EC 3.4.99.45, gamma-endorphin-generating enzyme, IDE, INS20-19, insulin degrading enzyme, Insulin protease, Insulin proteinase, Insulin-degrading enzyme, Insulin-degrading neutral proteinase, Insulin-glucagon protease, Insulin-specific protease, Insulinase, Insulysin, Metalloinsulinase, More, pitrilysin metallopeptidase 1, Pitrm1
ECTree
3.4.24.56 insulysinAdvanced search results
results (
results (Source Tissue
Source Tissue on EC 3.4.24.56 - insulysin
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
SOURCE TISSUE 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
SOURCE
-
endothelium of the cerebrovascular blood vessel, expression of enzyme
-
N2a cells stably expressing human amyloid prepcursor protein Swedish mutation
-
post-mortal samples, regional and cellular distribution pattern, immunohistochemic analysis, overview
-
activity and amount of enzyme decrease in the cytosolic fraction with castration and increase with testpsterone treatment
-
activity and amount of enzyme decrease during metestrus and increase with estradiol treatment and proestrus
additional information
-
endothelium of the cerebrovascular blood vessel, expression of enzyme
-
isolated brain microvessels, in patients with Alzheimers disease with cerebral amyloid angiopathy enzyme protein level is up to 44% increased, but enzyme activity is significantly reduced
-
post-mortal brains, regional and cellular distribution pattern, immunohistochemic analysis, overview
-
left and right dorsolateral prefrontal cortex, expression of IDE protein in postmortem brains of healthy subjects and patients with schizophrenia, immunohistochemic analysis, overview
-
mutant brains expressing the Swedish mutant precursor of amyloid beta-peptide, enzyme level, activity and distribution, immunohistochemic analysis, overview
-
membranes isolated from mouse brain with endogenous reduced levels of cholesterol due to targeted deletion of one seladin-I allele show a reduced amount of IDE
-
high expression level, increased expression level during development
-
native enzyme, insulysin is able to form a stable complex with amyloid beta
-
left and right dorsolateral prefrontal cortex, immunohistochemic IDE expression analysis, overview
-
isolated brain microvessels, in patients with Alzheimers disease with cerebral amyloid angiopathy enzyme protein level is up to 44% increased, but enzyme activity is significantly reduced
in Alzheimer's disease patients the protein level of insulin-degrading enzyme is decreased compared to control. However, mRNA of insulin-degrading enzyme is higher in cortex of Alzheimer's disease patients
-
after the development of first amyloid beta plaques in brain of transgenic mice with alzheimer's disease-like neuropathology, cortical mRNAand protein levels of IDE are significantly up-regulated in the transgenic mice compared to their non-transgenic littermates. Up-regulation of IDE mRNA-levels occurrs in parallel with increased amyloid beta40 and amyloid beta42 production. A significant positive correlation is observed between protein levels of IDE and full-length amyloid precursor protein in the cerebral cortex
-
cells express enzyme and respond to exposure to low levels of amyloid beta-protein by upregulation of enzyme expression
-
cerebrovascular, the this cell surface form is the major form of insulysin responsible for degrading amyloid beta-peptides
-
insulysin is reduced in the hippocampus of Alzheimer's disease patients with an apolipoprotein E-4 allele
in Alzheimer's disease patients the protein level of insulin-degrading enzyme is decreased compared to control
-
-
31317, 31318, 31322, 31326, 31327, 31333, 31336, 31339, 31340, 31341, 696135, 707150, 710682, 720820
-
high expression level, increased expression level during development
additional information
-
insulin occurs only in grade 3 tumors, whereas grade 2 carcinomas and the normal mammary gland are each insulin-negative, overview
additional information
-
tissue expression pattern in wild-type mice, tissue-specific regulation, overview
additional information
-
insulysin is expressed in all tissues assessed, including non-malignant tissues and all tumor cells except for Raji and Hl-60 cell. Normal lymphocytes are insulysin-negative
additional information
-
insulysin activity declines with aging in the hippocampus of a mouse model of Alzheimers disease
additional information
-
IDE activity levels in decreasing order in liver, pancreas, kidney, testis, adrenal gland, spleen, ovary, lung, heart, muscle, brain, and adipose tissue
